Adagene Inc.

01/27/2022 | Press release | Distributed by Public on 01/27/2022 06:07

Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 - Form 6-K